(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Advance Auto Parts Q1 Results Fall Short of Consensus, Lowers Outlook; iRhythm Technologies Reveals FDA Warning Letter

  • May 31st, 2023
  • 552 views

The first quarter of 2023 proved to be challenging for Advance Auto Parts, Inc. (NYSE: AAP), as the company reported diluted earnings per share (EPS) of $0.72, falling short of the consensus estimate of $2.57. 

Tom Greco, the president and chief executive officer, acknowledged the difficulties faced during this period. Despite net sales growing by 1.3% in the quarter, the operating margin rate of 2.6% was below expectations. This was primarily due to higher-than-planned investments aimed at narrowing competitive price gaps in the professional sales channel and an unfavorable product mix.

To enhance its financial flexibility, Advance Auto Parts' board of directors made the decision to reduce its quarterly cash dividend to $0.25 per share. Furthermore, the company adjusted its full-year 2023 guidance, revising the diluted EPS outlook from a range of $10.20 - $11.20 to a range of $6.00 - $6.50.

In pre-market, $AAP is currently trading at $83.50, reflecting a significant decrease of $28.70 (-25.58%).

In a regulatory filing, iRhythm Technologies, Inc. (Nasdaq: IRTC) disclosed that it had received - on May 25, 2023 - a warning letter from the U.S. Food and Drug Administration (FDA). The warning letter was the result of an inspection conducted at the company's Cypress, California facility in August 2022. The FDA identified non-conformities to regulations for medical devices, including medical device reporting requirements and medical device quality system requirements, specifically related to iRhythm's Zio AT System. 

The company takes these matters seriously and intends to respond within the specified time period, working diligently to address the FDA's concerns.

On Tuesday, $IRTC closed at $121.68, showing a modest increase of $2.38 (+1.99%).

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13